Revolutionizing Asset Evaluation
If you’re engaged in New Product Planning, Drug Development, Launch Planning, Portfolio Prioritization, Life Cycle Management or working towards a specific transaction (e.g. license and/or investment), I’d love to chat with you and explore how the Asset Evaluation Tool could support you through these processes.
With online access via an annual license, unlimited remote asset forecasting is now available, providing you with greater forecasting freedom and flexibility. Mirador Analytics’ Asset Evaluation Tool is perfectly positioned to assist you with strategic decision making, optimizing value and assessing risk. Should you require assistance with inputs into the Asset Evaluation Tool, our experienced consulting team can support here. If required, we can also build a bespoke Forecasting Tool to match your company’s precise specifications.
Drug development and commercialization is an uncertain process. As a commercialization catalyst, Mirador Analytics helps foster the drug innovation process and provides drug commercialization assessment and launch planning services to biopharma SMEs around the world. With this in mind, alongside our Asset Evaluation services, we can also assist with Portfolio Prioritization, Life Cycle Management and Business Development Transactional Services.
Mirador Analytics is unique in comparison to other analytics and consulting organizations. We have extensive experience in the pharmaceutical sector and our team members have worked in similar senior-level roles to our clients. Alongside this, by combining both analytical and consultancy services we deliver relevant industry-specific outputs during every interaction with you.
To learn more about the Asset Evaluation Tool or to set up a complimentary trial, please get in touch via the contact us page.